Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccin...
Main Authors: | Daniele Lapa, Daria M. Grousova, Giulia Matusali, Silvia Meschi, Francesca Colavita, Aurora Bettini, Giulia Gramigna, Massimo Francalancia, Anna Rosa Garbuglia, Enrico Girardi, Vincenzo Puro, Andrea Antinori, Anna V. Kovyrshina, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Amir I. Tukhvatulin, Olga V. Zubkova, Vladimir A. Gushchin, Denis Y. Logunov, Boris S. Naroditsky, Francesco Vaia, Alexander L. Gintsburg |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/5/817 |
Similar Items
-
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
by: Amir I. Tukhvatulin, et al.
Published: (2022-12-01) -
Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
by: Giulia Matusali, et al.
Published: (2022-02-01) -
Immunogenicity evaluation of Gam-COVID-Vac (Sputnik V)
by: I. A. Kirillov, et al.
Published: (2022-12-01) -
Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
by: Vladimir A. Gushchin, et al.
Published: (2022-04-01) -
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
by: Amir I. Tukhvatulin, et al.
Published: (2021-12-01)